These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 11351775)

  • 1. Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE).
    Bondeson J; Maini RN
    Int J Clin Pract; 2001 Apr; 55(3):211-6. PubMed ID: 11351775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab treatment of rheumatoid arthritis.
    Maini SR
    Rheum Dis Clin North Am; 2004 May; 30(2):329-47, vii. PubMed ID: 15172044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab treatment of rheumatoid arthritis and Crohn's disease.
    Nahar IK; Shojania K; Marra CA; Alamgir AH; Anis AH
    Ann Pharmacother; 2003 Sep; 37(9):1256-65. PubMed ID: 12921510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept].
    Tijhuis GJ; van de Putte LB; Breedveld FC
    Ned Tijdschr Geneeskd; 2001 Sep; 145(39):1880-5. PubMed ID: 11605312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Suspected cases of severe side effects after infliximab (Remicade) in Germany].
    Andus T; Stange EF; Höffler D; Keller-Stanislawski B
    Med Klin (Munich); 2003 Aug; 98(8):429-36. PubMed ID: 12928808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adalimumab: human recombinant immunoglobulin g1 anti-tumor necrosis factor monoclonal antibody.
    Baker DE
    Rev Gastroenterol Disord; 2004; 4(4):196-210. PubMed ID: 15580154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Revision of the recommendations of the Commission on Pharmacotherapy of the German society for Rheumatology. Therapy with tumour necrosis factor blockers for inflammatory rheumatic illnesses].
    Manger B; Michels H; Nüsslein HG; Schneider M; Sieper J;
    Z Rheumatol; 2007 Feb; 66(1):72-5. PubMed ID: 17221253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TNF inhibitors in the treatment of arthritis.
    Lorenz HM
    Curr Opin Investig Drugs; 2000 Oct; 1(2):188-93. PubMed ID: 11249572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etanercept and infliximab for rheumatoid arthritis.
    Drug Ther Bull; 2001 Jul; 39(7):49-52. PubMed ID: 11471515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.
    Keating GM; Perry CM
    BioDrugs; 2002; 16(2):111-48. PubMed ID: 11985485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-TNFalpha therapy of rheumatoid arthritis: what can we learn about chronic disease?
    Feldmann M; Brennan FM; Paleolog E; Cope A; Taylor P; Williams R; Woody J; Maini RN
    Novartis Found Symp; 2004; 256():53-69; discussion 69-73, 106-11, 266-9. PubMed ID: 15027483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12.
    van Oosterhout M; Levarht EW; Sont JK; Huizinga TW; Toes RE; van Laar JM
    Ann Rheum Dis; 2005 Apr; 64(4):537-43. PubMed ID: 15769913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trial outcome of anti-tumour necrosis factor alpha therapy in rheumatic arthritis.
    Choy E
    Cytokine; 2004 Nov 21-Dec 7; 28(4-5):158-61. PubMed ID: 15588689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis.
    Chan CY; Browning JC; Larsen F; Hsu S
    Dermatol Online J; 2008 Sep; 14(9):12. PubMed ID: 19061594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis.
    Channual J; Wu JJ; Dann FJ
    Dermatol Ther; 2009; 22(1):61-73. PubMed ID: 19222518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacological profile of anti-human TNF alpha monoclonal antibody, infliximab (Remicade)].
    Sugita T
    Nihon Yakurigaku Zasshi; 2003 Jan; 121(1):57-64. PubMed ID: 12617039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha?
    Buch MH; Conaghan PG; Quinn MA; Bingham SJ; Veale D; Emery P
    Ann Rheum Dis; 2004 Oct; 63(10):1344-6. PubMed ID: 15033655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
    Bendtzen K; Geborek P; Svenson M; Larsson L; Kapetanovic MC; Saxne T
    Arthritis Rheum; 2006 Dec; 54(12):3782-9. PubMed ID: 17133559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
    Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
    Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.